statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	601
SG - Singapore	157
DE - Germania	146
CN - Cina	94
SE - Svezia	72
IT - Italia	58
BR - Brasile	56
UA - Ucraina	51
FR - Francia	49
VN - Vietnam	29
IN - India	22
GB - Regno Unito	19
IE - Irlanda	18
FI - Finlandia	17
ID - Indonesia	10
CA - Canada	8
BD - Bangladesh	7
RU - Federazione Russa	7
AR - Argentina	6
BE - Belgio	6
JP - Giappone	5
MX - Messico	5
NL - Olanda	5
HK - Hong Kong	4
IQ - Iraq	4
PK - Pakistan	4
TR - Turchia	4
AT - Austria	3
AU - Australia	3
CO - Colombia	3
PH - Filippine	3
EC - Ecuador	2
LT - Lituania	2
MY - Malesia	2
NI - Nicaragua	2
SA - Arabia Saudita	2
TN - Tunisia	2
AE - Emirati Arabi Uniti	1
AF - Afghanistan, Repubblica islamica di	1
BO - Bolivia	1
CH - Svizzera	1
CL - Cile	1
DO - Repubblica Dominicana	1
DZ - Algeria	1
EG - Egitto	1
ES - Italia	1
GE - Georgia	1
IR - Iran	1
JM - Giamaica	1
JO - Giordania	1
KE - Kenya	1
KG - Kirghizistan	1
KH - Cambogia	1
KR - Corea	1
KZ - Kazakistan	1
LA - Repubblica Popolare Democratica del Laos	1
LV - Lettonia	1
MA - Marocco	1
NO - Norvegia	1
PE - Perù	1
PL - Polonia	1
RS - Serbia	1
SV - El Salvador	1
UY - Uruguay	1
VE - Venezuela	1
YT - Mayotte	1
ZA - Sudafrica	1
Totale	1.518

Nome	#
Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study.	199
Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study	195
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target	172
In vivo platelet activation and aspirin responsiveness in type 1 diabetes mellitus	171
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes	170
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement	162
In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythemia	121
In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia	118
Farmaci antipiastinici	115
Identifying determinants of variability to tailor aspirin therapy	111
Totale	1.534

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	1	0	0	0	0	0	0	0	0	0	0	0	1
2021/2022	105	12	7	4	2	4	4	2	23	3	5	17	22
2022/2023	255	47	42	15	40	23	29	10	15	22	1	11	0
2023/2024	91	3	27	3	12	4	10	5	0	2	2	11	12
2024/2025	182	7	4	14	15	26	3	1	12	16	15	36	33
2025/2026	415	75	6	24	38	88	16	72	16	38	20	18	4
Totale													1.534

IRIS UniCatt